1
Ling Leona E, Fu Kai, Gill Alan, Gotwals Philip J: Methods of treating vascular injuries. Biogen Idec Ma, Ling Leona E, Fu Kai, Gill Alan, Gotwals Philip J, O BRIEN Jonathan P, April 27, 2006: WO/2006/044509 (28 worldwide citation)

The present invention relates to use of compounds and implantable devices including those compounds in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, ...


2
Improvements in or relating to structures. Gill Alan S, Gill Stirling, Abbatt Cyril Paul, June 28, 1950: GB639569-A (1 worldwide citation)

639,569. Constructional units ; floors ; walls. GILL, A. S., GILL S. P., and ABBATT, C. P. May 22, 1947, No. 13784. [Classes 20 (ii) and 20 (iv)] [Also in Groups XIV, XV and XXVIII] A unit for use in forming various structures comprises tubular members 1 rigidly and permanently secured together to p ...


3

4
Lepage Doreen, Gill Alan: Lymphotoxin beta receptor agents in combination with chemotherapeutic agents. Biogen Idec Ma, Lepage Doreen, Gill Alan, MANDRAGOURAS Amy E, July 15, 2004: WO/2004/058183

This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxi ...


5
Lee Wen Cherng, Gill Alan: A novel vla-4 inhibitor: omepupa-v. Biogen, Lee Wen Cherng, Gill Alan, FLYNN Kerry, December 2, 1999: WO/1999/061421

OMePUPA-V, (R)-$i(N)-[[4-[[(2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl-3-methyl)-$g(b)-Alanine, a cell adhesion inhibitor, pharmaceutical compositions, and methods of treatment of cell-adhesion mediated pathologies.